Latest

3 stories

Hide weekly roundups

Tuesday, August 11

Cardiff Oncology reports Q2 2026 results, plans Phase 3 mCRC trial for early 2027

Following positive Phase 2 data and an End-of-Phase 2 meeting with FDA, Cardiff plans to start a registrational trial of onvansertib in first quarter 2027, subject to financing.

SEC filing

Thursday, July 16

PartnershipCardiff Oncology

Cardiff Oncology prices $10 million registered direct offering

The clinical-stage biotech will sell shares and warrants at $1.05 apiece, with insiders paying a higher price, closing July 16, 2026.

SEC filing

FinancingCardiff Oncology

Cardiff Oncology prices $10.05 million gross stock and warrant offering

The company expects about $9.1 million in net proceeds after fees, with shares priced at $1.05 and insiders paying $1.455 per share.

SEC filing